We read with interest the paper by Vaidya and co-workers 1 in which they reported their experience with unpurged ABMT for childhood ALL in 31 patients in second remission. Previously, our group published our experience in the treatment of childhood ALL with purged ABMT in 55 patients in second remission. 2 The criteria for early and late relapse were the same in both studies and patient age, sex, number of cases with early and late relapse, and interval from relapse to ABMT were comparable. There were differences between both studies in the conditioning regimens. The patients in the Vaidya et al series received single fraction TBI at a median dose of 10.5 Gy, while our patients received fractionated TBI at a median dose of 12 Gy (200 cGy twice daily for 3 days). In the Vaidya series, the patients received chemotherapy with melphalan at a dose of 140 mg/m 2 and our patients received cyclophosphamide (120 mg/kg) or cyclophosphamide ϩ Ara-C (18 g/m 2 ) or VP-16 (45-50 mg/m 2 ). The survival rate in both studies was the same (45%). The observation that single-dose TBI does not result in higher survival has been corroborated in a recent prospective randomized study. Vaidya et al reported late effects of cataracts that required surgery in 12 of their 15 surviving patients and growth hormone insufficiency in 14 of 15 surviving patients that required growth hormone replacement. Although our late effects were not mentioned in our paper, 2 unlike the Vaidya series we had no cases of cataracts in our 26 surviving patients and only two of these 26 patients developed growth hormone insufficiency. Both patients had previously received cranial irradiation as part of their initial treatment before they were referred to our hospital for purged ABMT. Furthermore, with the use of unpurged bone marrow Vaidya et al reported that four of 31 patients did not achieve sustained engraftment (one neutrophil and three platelet).
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Firstly, there has been no randomised study looking at the role of purging in ABMT in ALL. Its benefit is questionable since relapse of leukaemia is not necessarily due to reinfused leukaemia in the autograft and our hypothesis is that elimination of leukaemia by effective conditioning is equally important. The survival in our group of patients 1 is comparable to that of Maldonado et al. 2 In addition, in the Italian study that Maldonado et al quote, 3 EFS was not affected by purging. Purging does not compromise engraftment, as is also evident from the review by Billett et al, 4 but its contribution to disease-free survival is as yet uncertain.
We agree that our patients developed severe late sequelae needing hormone replacement and this is most probably a In our series, despite manipulation for marrow purging with monoclonal antibodies plus complement or immunomagnetic microspheres, all 55 of our patients engrafted, which shows that this procedure does not compromise engraftment.
Finally, our attention is drawn to the fact that Vaidya et al have currently replaced ABMT by unrelated donor BMT following cyclophosphamide/fractionated TBI for the treatment of relapsed childhood ALL. This procedure seems reasonable for very high risk patients, such as patients with early relapse in whom the results of ABMT have been demonstrated to be poor. Our view, which is shared by other authors, 4 is that ABMT is a good treatment option in patients with late extramedullary or bone marrow relapse on account of its low transplant-related morbidity and mortality.
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Ramón y Cajal Hospital University of Alcalá 28034 -Madrid, Spain result of giving total body irradiation (TBI) in a single fraction as has been suggested by other reports. 5, 6 We have since changed our policy and all children are now given fractionated TBI.
Finally, Maldonado et al quote the paper by the Italian group 3 to reinforce their suggestion that ABMT is a good option for children with late bone marrow and extra-medullary relapse. We agree that ABMT benefits children with extra-medullary relapse; however, in patients with bone marrow relapse, the survival was less than 20%. This raises the question whether ABMT in late bone marrow relapse of ALL is superior to intensive chemotherapy alone.
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